Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1807

    1.

    Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months.

    Lusingu JP, Gesase S, Msham S, Francis F, Lemnge M, Seth M, Sembuche S, Rutta A, Minja D, Segeja MD, Bosomprah S, Cousens S, Noor R, Chilengi R, Druilhe P.

    Malar J. 2009 Jul 17;8:163.

    PMID:
    19607731
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.

    Sirima SB, Tiono AB, Ouédraogo A, Diarra A, Ouédraogo AL, Yaro JB, Ouédraogo E, Gansané A, Bougouma EC, Konaté AT, Kaboré Y, Traoré A, Chilengi R, Soulama I, Luty AJ, Druilhe P, Cousens S, Nébié I.

    PLoS One. 2009 Oct 26;4(10):e7549. Erratum in: PLoS One. 2010;5(4). doi: 10.1371/annotation/3221b8d9-038d-4e67-82fa-de6b1233b459. Druilhe, Pierre [added]; Roma, Chilengi [corrected to Chilengi, Roma].

    PMID:
    19855847
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    3.

    Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa.

    Sirima SB, Nébié I, Ouédraogo A, Tiono AB, Konaté AT, Gansané A, Dermé AI, Diarra A, Ouédraogo A, Soulama I, Cuzzin-Ouattara N, Cousens S, Leroy O.

    Vaccine. 2007 Mar 30;25(14):2723-32. Epub 2006 Jun 16.

    PMID:
    17280744
    [PubMed - indexed for MEDLINE]
    4.

    Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique.

    Macete E, Aponte JJ, Guinovart C, Sacarlal J, Ofori-Anyinam O, Mandomando I, Espasa M, Bevilacqua C, Leach A, Dubois MC, Heppner DG, Tello L, Milman J, Cohen J, Dubovsky F, Tornieporth N, Thompson R, Alonso PL.

    Trop Med Int Health. 2007 Jan;12(1):37-46.

    PMID:
    17207146
    [PubMed - indexed for MEDLINE]
    Free Article
    5.

    Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.

    Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, Manaca MN, Lafuente S, Barbosa A, Leach A, Lievens M, Vekemans J, Sigauque B, Dubois MC, Demoitié MA, Sillman M, Savarese B, McNeil JG, Macete E, Ballou WR, Cohen J, Alonso PL.

    Lancet. 2007 Nov 3;370(9598):1543-51. Epub 2007 Oct 18.

    PMID:
    17949807
    [PubMed - indexed for MEDLINE]
    6.

    Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.

    Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Kone AK, Guindo AB, Traore K, Sissoko M, Diallo DA, Diarra I, Kouriba B, Daou M, Dolo A, Baby M, Sissoko MS, Sagara I, Niangaly A, Traore I, Olotu A, Godeaux O, Leach A, Dubois MC, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, Takala SL, Lyke KE, House B, Lanar DE, Dutta S, Heppner DG, Plowe CV.

    PLoS One. 2010 Feb 4;5(2):e9041.

    PMID:
    20140214
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    7.

    Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

    Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, Druilhe P, Spertini F.

    Infect Immun. 2005 Dec;73(12):8017-26.

    PMID:
    16299295
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    8.

    Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

    Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, Bergmann-Leitner E, Stewart VA, Bittner S, Juompan L, Kortepeter MG, Nielsen R, Krzych U, Tierney E, Ware LA, Dowler M, Hermsen CC, Sauerwein RW, de Vlas SJ, Ofori-Anyinam O, Lanar DE, Williams JL, Kester KE, Tucker K, Shi M, Malkin E, Long C, Diggs CL, Soisson L, Dubois MC, Ballou WR, Cohen J, Heppner DG Jr.

    PLoS One. 2009;4(4):e5254. Epub 2009 Apr 23.

    PMID:
    19390585
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    9.

    Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso.

    Nebie I, Diarra A, Ouedraogo A, Tiono AB, Konate AT, Gansane A, Soulama I, Cousens S, Leroy O, Sirima SB.

    Parasite Immunol. 2009 Aug;31(8):474-80.

    PMID:
    19646212
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    10.

    Humoral immune responses during a malaria vaccine trial in Tanzanian infants.

    Galindo CM, Acosta CJ, Schellenberg D, Aponte JJ, Roca A, Oettli A, Urassa H, Armstrong Schellenberg J, Kahigwa E, Ascaso C, Mshinda H, Lwilla F, Vidal J, Menendez C, Tanner M, Alonso PL.

    Parasite Immunol. 2000 Sep;22(9):437-43.

    PMID:
    10972850
    [PubMed - indexed for MEDLINE]
    11.

    Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children.

    Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, Fitzpatrick S, Njie F, Kassanga A, Leach A, Milman J, Rabinovich R, McAdam KP, Kester KE, Heppner DG, Cohen JD, Tornieporth N, Milligan PJ.

    Vaccine. 2005 Jul 14;23(32):4148-57. Epub 2005 Apr 15.

    PMID:
    15964483
    [PubMed - indexed for MEDLINE]
    12.

    Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.

    Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, Owusu R, Shomari M, Leach A, Jongert E, Salim N, Fernandes JF, Dosoo D, Chikawe M, Issifou S, Osei-Kwakye K, Lievens M, Paricek M, Möller T, Apanga S, Mwangoka G, Dubois MC, Madi T, Kwara E, Minja R, Hounkpatin AB, Boahen O, Kayan K, Adjei G, Chandramohan D, Carter T, Vansadia P, Sillman M, Savarese B, Loucq C, Lapierre D, Greenwood B, Cohen J, Kremsner P, Owusu-Agyei S, Tanner M, Lell B.

    Lancet Infect Dis. 2011 Oct;11(10):741-9. Epub 2011 Jul 22. Erratum in: Lancet Infect Dis. 2011 Oct;11(10):727.

    PMID:
    21782519
    [PubMed - indexed for MEDLINE]
    13.

    Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.

    Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Olivier A, Benns S, Olomi R, Msham S, Lang T, Gould J, Hallez K, Guerra Y, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Dekker D, Malle L, Ismael S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM, Lemnge MM, Marsh K, Bejon P, von Seidlein L.

    PLoS One. 2010 Nov 29;5(11):e14090. Erratum in: PLoS One. 2010;5(12) doi: 10.1371/annotation/0543a689-83a6-4528-92a1-a0f978b47fcb. PLoS One. 2010; 5(12) doi: 10.1371/annotation/3b62fdef-4cdd-40cc-b69d-69afd2000c4f.

    PMID:
    21124768
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    14.

    A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.

    Bélard S, Issifou S, Hounkpatin AB, Schaumburg F, Ngoa UA, Esen M, Fendel R, de Salazar PM, Mürbeth RE, Milligan P, Imbault N, Imoukhuede EB, Theisen M, Jepsen S, Noor RA, Okech B, Kremsner PG, Mordmüller B.

    PLoS One. 2011;6(7):e22525. Epub 2011 Jul 28.

    PMID:
    21829466
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    15.

    Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.

    Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, Tucker K, Waitumbi JN, Diggs C, Wittes J, Malkin E, Leach A, Soisson LA, Milman JB, Otieno L, Holland CA, Polhemus M, Remich SA, Ockenhouse CF, Cohen J, Ballou WR, Martin SK, Angov E, Stewart VA, Lyon JA, Heppner DG, Withers MR; MSP-1 Malaria Vaccine Working Group.

    PLoS One. 2009;4(3):e4708. Epub 2009 Mar 5.

    PMID:
    19262754
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    16.

    Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial.

    Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Kone AK, Guindo AB, Traore K, Dicko A, Sagara I, Sissoko MS, Baby M, Sissoko M, Diarra I, Niangaly A, Dolo A, Daou M, Diawara SI, Heppner DG, Stewart VA, Angov E, Bergmann-Leitner ES, Lanar DE, Dutta S, Soisson L, Diggs CL, Leach A, Owusu A, Dubois MC, Cohen J, Nixon JN, Gregson A, Takala SL, Lyke KE, Plowe CV.

    PLoS One. 2008 Jan 23;3(1):e1465.

    PMID:
    18213374
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    17.

    A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.

    Malkin E, Hu J, Li Z, Chen Z, Bi X, Reed Z, Dubovsky F, Liu J, Wang Q, Pan X, Chen T, Giersing B, Xu Y, Kang X, Gu J, Shen Q, Tucker K, Tierney E, Pan W, Long C, Cao Z.

    Vaccine. 2008 Dec 9;26(52):6864-73. Epub 2008 Oct 16.

    PMID:
    18930094
    [PubMed - indexed for MEDLINE]
    18.

    Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians.

    Dicko A, Diemert DJ, Sagara I, Sogoba M, Niambele MB, Assadou MH, Guindo O, Kamate B, Baby M, Sissoko M, Malkin EM, Fay MP, Thera MA, Miura K, Dolo A, Diallo DA, Mullen GE, Long CA, Saul A, Doumbo O, Miller LH.

    PLoS One. 2007 Oct 17;2(10):e1045.

    PMID:
    17940609
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    19.

    Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.

    Roussilhon C, Oeuvray C, Müller-Graf C, Tall A, Rogier C, Trape JF, Theisen M, Balde A, Pérignon JL, Druilhe P.

    PLoS Med. 2007 Nov 13;4(11):e320.

    PMID:
    18001147
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    20.

    Efficacy trial of malaria vaccine SPf66 in Gambian infants.

    D'Alessandro U, Leach A, Drakeley CJ, Bennett S, Olaleye BO, Fegan GW, Jawara M, Langerock P, George MO, Targett GA, et al.

    Lancet. 1995 Aug 19;346(8973):462-7.

    PMID:
    7637479
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk